Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
Minimal residual disease (MRD) is associated with adverse outcome in AML after myeloablative (MA) hematopoietic cell transplantation (HCT). We compared this association with that seen after nonmyeloablative (NMA) conditioning in 241 adults receiving NMA (n=86) or MA (n=155) HCT for AML in first remi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254901/ |